Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, Mainou BA, Konopka-Anstadt JL, Hendley WS, Vincent A, Clemens R, Clemens SAC, Ross AG, Clemens JD, Tritama E. Zaman K, et al. Among authors: mainou ba. Lancet. 2023 Jan 14;401(10371):131-139. doi: 10.1016/S0140-6736(22)02397-2. Epub 2022 Dec 7. Lancet. 2023. PMID: 36495882 Free PMC article. Clinical Trial.
Inactivated Poliovirus Vaccine Closing the Type 2 Immunity Gap in Vietnam.
Huyen DTT, Anh DD, Trung NT, Hong DT, Thanh TT, Truong LN, Jeyaseelan V, Lopez Cavestany R, Hendley WS, Mainou BA, Mach O. Huyen DTT, et al. Among authors: mainou ba. J Pediatric Infect Dis Soc. 2022 Sep 29;11(9):413-416. doi: 10.1093/jpids/piac046. J Pediatric Infect Dis Soc. 2022. PMID: 35801634 Free PMC article.
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Erdem R, De Coster I, Withanage K, Mercer LD, Marchant A, Taton M, Cools N, Lion E, Cassels F, Higgins D, Ivinson K, Locke E, Mahmood K, Wright PF, Gast C, White JA, Ackerman ME, Konopka-Anstadt JL, Mainou BA, Van Damme P. Erdem R, et al. Among authors: mainou ba. Vaccine. 2023 Mar 3;41(10):1657-1667. doi: 10.1016/j.vaccine.2023.01.048. Epub 2023 Feb 4. Vaccine. 2023. PMID: 36746739 Free PMC article. Clinical Trial.
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL, Zaman K, Hoque M, Estivariz CF, Burns CC, Konopka-Anstadt JL, Mainou BA, Kovacs SD, An Q, Lickness JS, Yunus M, Snider CJ, Zhang Y, Coffee E, Abid T, Wassilak SGF, Pallansch MA, Oberste MS, Vertefeuille JF, Anand A. Wilkinson AL, et al. Among authors: mainou ba. Lancet Infect Dis. 2023 Sep;23(9):1062-1071. doi: 10.1016/S1473-3099(23)00139-1. Epub 2023 May 10. Lancet Infect Dis. 2023. PMID: 37178706 Free PMC article. Clinical Trial.
Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey.
Kennedy SB, Macklin GR, Mason Ross G, Lopez Cavestany R, Moukom RA, Jones KAV, Mainou BA, Massaquoi MBF, Kieh MWS, Mach O. Kennedy SB, et al. Among authors: mainou ba. Lancet Glob Health. 2023 Jun;11(6):e917-e923. doi: 10.1016/S2214-109X(23)00116-X. Lancet Glob Health. 2023. PMID: 37202026 Free PMC article.
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ, Zaman K, Wilkinson AL, Binte Aziz A, Yunus M, Haque W, Jones KAV, Wei L, Estivariz CF, Konopka-Anstadt JL, Mainou BA, Patel JC, Lickness JS, Pallansch MA, Wassilak SGF, Steven Oberste M, Anand A. Snider CJ, et al. Among authors: mainou ba. Vaccine. 2023 Sep 22;41(41):6083-6092. doi: 10.1016/j.vaccine.2023.08.055. Epub 2023 Aug 29. Vaccine. 2023. PMID: 37652822 Free PMC article. Clinical Trial.
Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.
Sharma AK, Verma H, Estivariz CF, Bajracharaya L, Rai G, Shah G, Sherchand J, Jones KAV, Mainou BA, Chavan S, Jeyaseelan V, Sutter RW, Shrestha LP. Sharma AK, et al. Among authors: mainou ba. Lancet Microbe. 2023 Nov;4(11):e923-e930. doi: 10.1016/S2666-5247(23)00215-X. Epub 2023 Sep 26. Lancet Microbe. 2023. PMID: 37774729 Free PMC article. Clinical Trial.
Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, Rüttimann R. Rivera Mejía L, et al. Among authors: mainou ba. Lancet Infect Dis. 2024 Mar;24(3):275-284. doi: 10.1016/S1473-3099(23)00519-4. Epub 2023 Dec 15. Lancet Infect Dis. 2024. PMID: 38109921 Free PMC article. Clinical Trial.
55 results